Ausper Biopharma Co., Ltd.

This study tests a new drug called AHB-137 in 105 adults with chronic hepatitis B who have not been treated before. The goal is to see if the drug can lower the virus to undetectable levels and possibly achieve a functional cure, where the virus stays under control even after sto…

This study tests an experimental drug called AHB-137 in 20 adults with chronic hepatitis B who are already taking standard antiviral pills. The goal is to see if the injection can lower the hepatitis B virus to undetectable levels and help the body's immune system fight the infec…

This study tests a new drug called AHB-137 in adults with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if AHB-137 can lower the virus to undetectable levels and possibly allow patients to stop their daily medication. About 86 participants wi…

This study tests whether adding an experimental drug (AHB-137) to either a hepatitis B vaccine or an immune-boosting medicine (pegylated interferon) can help people with chronic hepatitis B stop their daily antiviral pills without the virus coming back. About 127 adults with HBeA…

This study tests an experimental injection called AHB-137 in adults with a type of chronic hepatitis B (HBeAg-negative) who are already on standard antiviral pills. The goal is to see if AHB-137 can clear the hepatitis B surface antigen (HBsAg) from the blood and keep the virus u…